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Traumatic brain injury (TBI), a growing public health problem,
appears to result not only from major andprimary injury but also
from a complex interplay among inflammatory, biochemical, and
neurohormonal changes, as well as genetic components acting on
brain tissue. As a result, characterization and classification of TBI
requires multidimensional approaches that are able to encompass
the diverse and highly complex clinical picture of TBI across the
continuum of severities and broad spectrum of pathobiological
processes. Emerging evidence suggests that an increasing num-
ber of biologic substances, commonly referred to in today’s ver-
nacular as biomarkers, can provide unprecedented opportunities
for detecting and classifying injury, and identifying pathophysi-
ologic mechanisms potentially leading to more effective targeted
therapies.
In this Research Topic, we include comprehensive reviews of
the current literature on this topic ranging from proteomics tech-
niques applied for the first time to central nervous system (CNS)
biomarker discovery (1) to potential clinical applications of exist-
ing biomarkers of brain injury in specific settings such as ICU,
pediatric TBI (2), and the military-relevant battlefield casualty
(3). In particular, to address the unique circumstances and conse-
quences of sustaining a TBI in combat and the demand for specific
practices of management and care of soldiers, presentations (3, 4)
have been included from outstanding researchers of the Com-
bat Casualty Care Research Program (CCCRP) for Brain Trauma
and Neuroprotection, a program specifically focused on develop-
ing neuroprotective and neurorestorative strategies for military-
relevant TBI. We have also added a chapter on blast TBI to empha-
size the potential problem of TBI following exposure to blast
(5). Finally, we expanded discussions to explore the potential of
brain damage biomarkers as tools for predicting long-term conse-
quences of TBI (6) and to outline their roles in other CNS diseases
such as neurodegeneration (Parkinson’s disease) (7), subarachnoid
hemorrhage (8), and hypoxic ischemic encephalopathy (9, 10).
We have strived to assemble a multidisciplinary group of inter-
nationally recognized researchers and clinicians highly relevant to
this research domain (11–13). As the translation of brain dam-
age biomarkers has already transformed from research tools to
being aids in clinical decision-making, this Research Topic will
be evolutionary reading for neurotrauma scientists and clinicians
interested in the potential of a simple biofluid-based diagnostic test
to refine the clinical characterization of TBI offering more accurate
disease phenotyping. Such improved molecular characterization
integrated with traditional approaches, including clinical exami-
nation and structural and functional neuroimaging, will allow the
field to develop improved clinical practice guidelines and tailor
therapeutic interventions to the patient’s individual pathophys-
iology, thereby leading to effective management and improved
patient outcome.
This Research Topic would not have been possible without the
support and help of many people. First, we thank the chapter
authors for devoting their time and effort to produce valuable
contributions that provide comprehensive frameworks and criti-
cal insights. We also thank the members of the editorial board for
their dedicated assistance and for providing informed perspectives
on the chapters. Last, and most important, we thank all patients
with TBI and their families for their invaluable contributions. To
improve their outcome and quality of life represents our ultimate
goal and our greatest source of inspiration to foster knowledge in
this critical research area.
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